Fidelity SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

Advanced Cell Technology Inc. (ACTC)

Add ACTC Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator locksflooring, sports guy, Kapla, LODE MAKING ME RICH, homeslice10, lasers
Search This Board:
Last Post: 10/30/2014 7:04:48 PM - Followers: 645 - Board type: Free - Posts Today: 21

Advanced Cell Technology, Inc. (ACTC)




Company Headquarters:

Advanced Cell Technology, Inc.
P.O. Box 1700
Santa Monica, CA 90406

Tel: (310) 576 0611
Fax: (310) 576 0662


Massachusetts Laboratory Facility
33 Locke Dr.
Marlborough, MA 01752
Tel: (508) 756-1212
Fax: (508) 229-2333


Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC) is a biotechnology company developing cellular therapies for the treatment of diseases that impact millions of people worldwide. The company is currently conducting the only ongoing, FDA-cleared human embryonic stem cell (hESC)-based human clinical trials. The two trials, initiated in July 2011 at UCLA's Jules Stein Eye Institute, use retinal pigment epithelial (RPE) cells derived from hESCs to treat forms of macular degeneration. ACT also recently received approval from the UK Medicines & Healthcare Products Regulatory Agency (MHRA) to conduct the first hESC trial in Europe. The company is also developing its Hemangioblast (HG) platform for the treatment of blood and cardiovascular diseases, its Phase II-cleared Myoblast stem cell therapy for the treatment of chronic heart failure and other cardiac conditions, and other programs.

ACT's principal laboratory and GMP facility is in Marlborough, Massachusetts, and its corporate offices are in Santa Monica, California. ACT is led by an experienced management team and a world-class scientific team helmed, respectively, by interim chairman and CEO Gary Rabin and chief scientific officer Robert Lanza, M.D.


ACT owns or licenses more than 150 patents and patent applications related to stem cell therapy and regenerative medicine, and is positioning itself to have a dominant patent position around its stem cell-derived RPE program in leading markets around the world.
In 2010 ACT secured three far-reaching patents related to its RPE program, and more recently was issued the first patent for generating hemangioblast cells to treat a broad spectrum of vascular and hematopoietic disorders.

The company's RPE and HG programs are hESC-based, and its Myoblast program for cardiac disease is an adult autologous stem cell therapy. As documented in NATURE and Cell Stem Cell, ACT developed the "single-cell blastomere" technique, the first-ever proven alternative method for successful hESC generation without harm to the embryo, for which it was recently issued a broad patent
RPE Program - ACT has developed a fully-differentiated RPE cell derived from human embryonic stem cells, which can be used as a cellular therapy to treat retinal degenerative diseases. In July 2011 ACT initiated two Phase I/II clinical trials to test the safety of the therapy for Stargardt's Macular Dystrophy (SMD), and for Dry Age-Related Macular Degeneration (Dry AMD). Dry AMD represents a $25-30 Billion market in the US and Europe alone, and there are no approved therapies currently available for either condition. Two patients have thus far been treated at UCLA, Institutional Review Board (IRB) approval for the SMD clinical trial has also been issued by Oregon Health & Science University (OHSU) and European regulatory clearance has been granted to initiate the first hESC trial in Europe.
Other recent milestones in ACT's RPE program include: the NIH proposed expanding its definition of hESCs for funding purposes, in part to accommodate ACT's lines derived using its patented "embryo-safe" single-cell blastomere technique; and both the FDA and the European Medicines Agency (EMA) granting ACT's RPE cells "Orphan" status for treatment of Stargardt's Disease.
Hemangioblast Program - ACT's Hemangioblast program is for the treatment of blood and cardiovascular diseases. A paper published in NATURE Methods revealed the company's successful generation of functional Hemangioblast cells from human embryonic stem cells, and a paper published earlier this year in Cell Research indicated that hESCs could be a potentially unlimited source of platelets for transfusion.
Myoblast Program - ACT's Myoblast treatment may prove particularly beneficial for patients who have experienced a serious heart attack and are at risk for heart failure. ACT has secured FDA approval to commence with Phase II clinical trials. The Myoblast program has several advantages over currently-available approaches, including symptom management and disease modification.

Dr. Lanza explains some of the technology we are pursuing:

For more information visit



Share Structure as of November 30, 2011:

Outstanding Shares

Reserved Shares

Authorized and Unreserved Shares



Authorized Preferred Shares



The following table sets forth information regarding beneficial ownership of our capital stock as of November 30, 2011 by:

·  5% or greater stockholders;
·  Each of our directors and named executive officers; and
·  All of our directors and executive officers, as a group.


Name and Address (1) of Beneficial Owner                                                                                         Common Stock Beneficially Owned                   Percentage of Shares Beneficially Owned 
5% or Greater Stockholders
Directors and Named Executive Officers
William M. Caldwell, IV**                                                                                                                             95,415,141 (1)                                                           5.58%%

Robert P. Lanza, M.D.                                                                                                                                  51,199,082 (2)                                                           2.97%%

Alan C. Shapiro                                                                                                                                           20,150,927 (3)                                                           1.18%%
Erkki Ruoslahti                                                                                                                                            2,500,000 (4)                                                                *
Gary Rabin                                                                                                                                                 23,087,430 (5)                                                           1.35%
Directors and Executive Officers as a Group (5 Persons)                                                                                192,352,580                                                               11.08%%


* Less than 1%

** Mr. Caldwell passed away on December 13, 2010

(1) Includes 5,108,546 shares subject to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

(2) Includes 17,583,207 shares subject to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

(3) Includes (i) 17,032,587 shares subject to convertible debentures, board fees, common stock grant held by The Shapiro Family Trust and of
which Dr. Shapiro may be deemed the beneficial owner, (ii) 3,018,340 shares subject to warrants in connection with the 2005-2008
convertible debentures, and (iii) 100,000 shares subject to stock options that are currently exercisable or exercisable within 60 days of
November 30, 2011.

(4) Includes 100,000 shares issuable upon exercise of options exercisable within 60 days of November 30, 2011. Effective August 1, 2011,
Erkki Ruoslahti resigned from the Board of Directors of the Company.

(5) Includes indirect ownership of (i) 1,239,501 shares issued to PDPI, LLC on December 22, 2010, upon exercise of certain warrants, which
such number of shares represents Mr. Rabin's proportional interest in the total number of shares held by PDPI, LLC, based on his 33.33%
equity interest in the entity. Mr. Rabin disclaims beneficial ownership in the shares held by PDPI, LLC, and (ii) 7,000,000 shares subject
to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

There are no arrangements known to the Company, including any pledge by any person of securities of the Company, the operation of
which may at a subsequent date result in a change in control of the Company.

Media Relations

Bill Douglass
Gotham Communications, LLC
bill [at] gothamcomm [dot] com


Martina Schwarzkopf, Ph.D.
Russo Partners, LLC
(212) 845-4292
martina.schwarzkopf [at] russopartnersllc [dot] com

Investor Relations

James Young
jyoung [at] ceocast [dot] com
(212) 732-4300






All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.




Rules of the board according to IHUB:


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ACTC News: OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell ... 07/01/2014 08:00:00 AM
ACTC News: OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell ... 07/01/2014 08:00:00 AM
ACTC News: Current Report Filing (8-k) 05/29/2014 05:00:40 PM
ACTC News: Quarterly Report (10-q) 05/08/2014 04:41:06 PM
#74805  Sticky Note ACT Announces Positive Results from Two Clinical Trials LittleDutchDenny 10/14/14 09:50:43 PM
#67180  Sticky Note $ACTC's May2014 Presentation Posted since on $ACTC website. Enjoy! lasers 06/06/14 12:22:51 AM
#75663   Some minor procedures can be done with tetracaine aberlowi 10/30/14 07:04:48 PM
#75662   ACTC blood patents are impressive. chuckanutman 10/30/14 04:34:23 PM
#75661   And we paid the agreed upon SEC settlement farviewhill 10/30/14 04:21:29 PM
#75660   Methinks that sometime towards the end of next elysse1kittycat 10/30/14 04:14:19 PM
#75659   LODE, don't know if this might be a farviewhill 10/30/14 03:43:30 PM
#75658   Wishing the best for your wife! anselab 10/30/14 02:24:35 PM
#75657   Easy to see ACTC's culmination of years of chuckanutman 10/30/14 02:04:47 PM
#75655   Good-ACTC news from American Foundation for the Blind. chuckanutman 10/30/14 11:43:39 AM
#75654   Actc has been dissed by many important peeps fulleroots 10/30/14 11:36:00 AM
#75653   Fast-track/Compassionate help for those in need is "the-way" chuckanutman 10/30/14 10:40:24 AM
#75652   Me too Senor Cat fulleroots 10/30/14 10:37:50 AM
#75651   Oh u think 2020? I was saying 2019ish.. fulleroots 10/30/14 10:31:11 AM
#75650   Hopefully things will be a lot clearer by elysse1kittycat 10/30/14 10:26:27 AM
#75649   When and if they actually start doing it fulleroots 10/30/14 10:25:24 AM
#75648   aberlowi thanks for the response. Been wondering about guy3 10/30/14 09:36:26 AM
#75647   My wife has bleeding in the eye LODE MAKING ME RICH 10/30/14 09:22:56 AM
#75646   Thanks a million, Chuck. That site is AWESOME! blaydonracer 10/30/14 08:48:17 AM
#75645   An injection into the eye would require anesthesia. aberlowi 10/30/14 08:41:10 AM
#75644   Anesthesia and surgery fee???? alteza 10/30/14 03:27:43 AM
#75643   Cutting the Pie: aberlowi 10/30/14 12:15:38 AM
#75641   About ACTC: "Just as importantly 17 of 18 chuckanutman 10/29/14 10:31:32 PM
#75640   1-1-2020 Gastrodamas 10/29/14 10:10:14 PM
#75639   Is it 20/20 yet? Gastrodamas 10/29/14 10:09:34 PM
#75638   More postive news for Advanced Cell Technology. chuckanutman 10/29/14 09:37:43 PM
#75637   Canada has all the ingredients to bring ACTC chuckanutman 10/29/14 12:04:03 PM
#75636   ACTC Regenerative Medicine Milestone: Longest running clinical trial chuckanutman 10/29/14 11:50:42 AM
#75635   I am disappointed to see how Foundation Fighting SMD2014 10/29/14 11:45:25 AM
#75634   Great interview. Thanks for posting. Reetala 10/29/14 11:40:02 AM
#75633   Click on "ACT CLINICAL TRIAL" alteza 10/29/14 11:34:22 AM
#75632   I love to read such article. Give hope SMD2014 10/29/14 10:26:59 AM
#75631   Score inching up. elysse1kittycat 10/29/14 10:20:34 AM
#75630   The pricing committee determines $5k or $10k. IPO chuckanutman 10/29/14 10:06:16 AM
#75629   What will be Ocata cut be? My guess guy3 10/29/14 09:54:06 AM
#75628   don't get me wrong-I am optimistic;however I have elysse1kittycat 10/29/14 09:51:38 AM
#75627   Could ACTC UK fastrack be $5,000 or $10,000 chuckanutman 10/29/14 09:44:09 AM
#75626   I concur. A few are grounded in reality though. knack1000 10/29/14 09:34:37 AM
#75624   " I have previously worked successfully with LeRoux chuckanutman 10/29/14 08:17:57 AM
#75623   It appears from all the calculated moves we crawford2012 10/28/14 10:17:01 PM
#75622   Well it looks like the same thing as homeslice10 10/28/14 09:11:25 PM
#75621   Well, Homeslice, any words of wisdom on our farviewhill 10/28/14 06:17:31 PM
#75620   I'm guessing Jeffries or someone other than than homeslice10 10/28/14 04:59:28 PM
#75619 andyshow 10/28/14 04:08:48 PM
#75618   aye/Lasers et al --approval in UK and/or other harlem111 10/28/14 12:20:00 PM
#75617   Extremely excited about the potential of what these aberlowi 10/28/14 12:11:27 PM
#75616   Excellent possibilities that UK MHRA will approve Commercial lasers 10/28/14 11:54:14 AM
#75615   Scotland has grants and tax credits available while AyeEye 10/28/14 10:49:40 AM
#75614   Hypotheticals: SMD approved in UK before USA (timed AyeEye 10/28/14 10:12:58 AM
#75613   would make a great mini vacation for our fulleroots 10/28/14 09:53:51 AM
#75612   The overall score isn't back to +100 yet elysse1kittycat 10/28/14 08:50:23 AM
#75611   meetings over several days indicates a sales pitch harlem111 10/28/14 08:32:14 AM